The serum concentrations of the tumor markers cancer antigen 125 (CA 125) and carcinoembryonic antigen (CEA) at the time of STO diagnosis were available in 67% and 57% of the patients, respectively (45% for both the tumor markers simultaneously). The gene discussed is CEACAM5; the disease is neoplasm.